September 25, 2020
Apeiron’s APN01 to treat COVID-19 in named patient use
APEIRON Biologics AG today announced that first, encouraging data with its clinical drug candidate APN01 (rhsACE2) to treat severe COVID-19 were published in the peer-reviewed journal The Lancet Respiratory Medicine.